BNTC
Benitec Biopharma Inc.12.41
+0.23+1.89%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
420.23MP/E (TTM)
-Basic EPS (TTM)
-1.09Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Benitec Biopharma posted a Q2 operating loss of $13.4M, up 24% y/y from $10.8M, driven by G&A expenses that doubled to $7.5M on $7.4M share-based comp; R&D held steady at $5.8M while net loss widened to $11.8M from $9.6M, offset partly by $1.4M interest income. Cash burned slowed sharply to $7.1M YTD, ending at $188.8M after $98.2M from stock offerings—no debt. Shares outstanding jumped to 34.3M from warrant exercises and new issuances, confirmed in EPS calc. Dilution funded runway. Clinical progress continues. BB-301 dosing advances safely. Yet competition intensifies.
8-K
BB-301 durable responses
Benitec Biopharma reported Q2 2026 results with $13.4M total expenses, up from $10.8M year-over-year, and $189M cash on hand. All four Cohort 1 patients in the BB-301 Phase 1b/2a trial completed 12-month follow-up as responders; Patient 1 showed deepening improvements at 24 months. FDA pivotal design meeting set for mid-2026. Cash fuels runway.
8-K
Annual meeting results mixed
8-K
Q1 loss widens; BB-301 shines
Benitec Biopharma reported Q1 2026 net loss of $9.0 million, up from $5.1 million year-over-year, with expenses climbing to $9.8 million on BB-301 clinical costs. Yet Cohort 1 in the Phase 1b/2a trial hit 100% responder rate for OPMD dysphagia; FDA granted Fast Track. Cash stood at $94.5 million, bolstered by $100 million equity raise. First Cohort 2 patient dosed.
10-Q
Q1 FY2026 results
Benitec Biopharma posted no revenue yet burned $9.8M in operating expenses for Q1 FY2026 ended September 30, 2025, up from $5.8M y/y, driven by G&A jumping to $6.4M (from $2.2M) on $5.2M share-based comp while R&D dipped to $3.4M (from $3.6M). Net loss hit $9.0M or $(0.22) diluted EPS, versus $5.1M or $(0.18) last year, with operating loss matching net as other income offset interest. Cash dipped to $94.5M q/q from $97.7M amid $3.4M operating burn, no debt, runway past twelve months. Cash funds BB-301 OPMD trial advances. Competition from better-resourced gene therapy rivals looms.
BLTE
Belite Bio, Inc
149.13+6.60
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
BNTX
BioNTech SE
92.23-1.52
CBIO
Crescent Biopharma, Inc.
12.92-0.29
DSGN
Design Therapeutics, Inc.
9.62+0.50
EDIT
Editas Medicine, Inc.
2.51+0.07
FENC
Fennec Pharmaceuticals Inc.
7.62-0.34
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
XCUR
Exicure, Inc.
6.06+0.33